Search
Bromocriptine
go.drugbank.com/drugs/DB01200ApprovedInvestigationalWithdrawnIt inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. … In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesClavulanic acid
go.drugbank.com/drugs/DB00766ApprovedInvestigationalVet approvedClavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible ...
Mixtures: AMOXICILLINA E ACIDO CLAVULANICO P-CARE, AMOXICILLINA E ACIDO CLAVULANICO P-CARESorbitol
go.drugbank.com/drugs/DB01638ApprovedInvestigationalIt was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures.
Categories: Drugs for Constipation, Tests for Bile Duct PatencyCycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisPyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedPyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use as an anthelmintic drug … Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900].
Mixtures: Heartgard Plus Chewable Tablet for Dogs - Up to 25 lbs, Heartgard Plus Chewable Tablet for Dogs - 26 - 50 lbsProducts: Jaa Pyral P Oral Paste - 125mg/gRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor.
Categories: Agents for Dermatitis, Excluding Corticosteroids, Cytochrome P-450 SubstratesResorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalAlthough it is primarily indicated for use as a topical application, resorcinol also possesses a well-documented anti-thyroidal activity that is generally not relied upon for any kind of formal therapeutic … It is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses
Categories: Anti-Acne Preparations for Topical UseSutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [ … [A245159] Treatment options for patients with CAD are limited.
Pucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigationalPucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.
Synonyms: Humanized pd-1 blocking antibody hx-008Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigational[A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival. … [A18696,L12633] In May 2021, the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors